Background: Autosomal dominant polycystic kidney disease (ADPKD) is the commonest inherited renal disorder; it is defined by progressive renal cyst formation and subsequent renal enlargement that leads to end-stage renal disease. Until recently, only symptomatic treatments for ADPKD existed. However, therapies that address the underlying pathophysiology of ADPKD are now available and accurate identification of the rate of disease progression is essential. Summary: Published data on the different imaging modalities for measuring kidney and cyst volumes in ADPKD are reviewed. The advantages and drawbacks of the different techniques for calculating kidney volume from renal imaging are also examined, including the use of manual planimetry, stereology, and the ellipsoid equation, as well as the prospect of semi- and fully automatic techniques. The translation of these approaches into clinical practice and their role in informing treatment decisions is discussed. Key Messages: These new therapies require the accurate monitoring of disease progression, which along with diagnosis and prognosis, relies on the effective use of renal imaging techniques. There is growing support for the use of total kidney volume as a measure of cyst burden and as a prognostic predictor of renal function in ADPKD, showing promise as a marker of disease progression.

Keywords:
Autosomal dominant polycystic kidney disease, Computed tomography, Magnetic resonance imaging, Renal, Ultrasound
1.
Spithoven EM, Kramer A, Meijer E, Orskov B, Wanner C, Abad JM, et al: Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival – an analysis of data from the ERA-EDTA Registry. Nephrol Dial Transplant 2014; 29:iv15–iv25.
2.
Grantham JJ, Geiser JL, Evan AP: Cyst formation and growth in autosomal dominant polycystic kidney disease. Kidney Int 1987; 31: 1145–1152.
3.
Grantham JJ: Autosomal dominant polycystic kidney disease. N Engl J Med 2008; 359: 1477–1485.
4.
Grantham JJ, Chapman AB, Torres VE: Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes. Clin J Am Soc Nephrol 2006; 1: 148–157.
5.
Rossetti S, Consugar MB, Chapman AB, Torres VE, Guay-Woodford LM, Grantham JJ, et al: Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143–2160.
6.
Reed B, McFann K, Kimberling WJ, Pei Y, Gabow PA, Christopher K, et al: Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 2008; 52: 1042–1050.
7.
Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al: Type of PKD1 mutation influences renal ­outcome in ADPKD. J Am Soc Nephrol 2013; 24: 1006–1013.
8.
Chapman AB, Devuyst O, Eckardt KU, Gansevoort RT, Harris T, Horie S, et al: Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2015; 88: 17–27.
9.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al: Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012; 367: 2407–2418.
10.
European Medicines Agency: Public Assessment Report Jinarc 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002788/WC500187923.pdf (accessed November 29, 2017).
11.
Food and Drug Admistration: NDA approval 2018. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2018/204441Orig1s000ltr.pdf (accessed June 13, 2017).
12.
Schrier RW, Abebe KZ, Perrone RD, Torres VE, Braun WE, Steinman TI, et al: Blood pressure in early autosomal dominant polycystic kidney disease. N Engl J Med 2014; 371: 2255–2266.
13.
Grantham JJ, Cook LT, Torres VE, Bost JE, Chapman AB, Harris PC, et al: Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int 2008; 73: 108–116.
14.
Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al: Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. J Am Soc Nephrol 2016; 31: 337–348.
15.
Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF, et al: Volume progression in polycystic kidney disease. N Engl J Med 2006; 354: 2122–2130.
16.
Chapman AB, Bost JE, Torres VE, Guay-Woodford L, Bae KT, Landsittel D, et al: Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2012; 7: 479–486.
17.
Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al: Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol 2015; 26: 160–172.
18.
Grantham JJ, Torres VE: The importance of total kidney volume in evaluating progression of polycystic kidney disease. Nat Publ Gr 2016; 12: 667–677.
19.
Perico N, Antiga L, Caroli A, Ruggenenti P, Fasolini G, Cafaro M, et al: Sirolimus therapy to halt the progression of ADPKD. J Am Soc Nephrol 2010; 21: 1031–1040.
20.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Dandurand A, et al: Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4: 4 Trial. Nephrol Dial Transplant 2017; 33: 447–489.
21.
Perrone RD, Neville J, Chapman AB, Gitomer BY, Miskulin DC, Torres VE, et al: Therapeutic area data standards for autosomal dominant polycystic kidney disease: a report from the Polycystic Kidney Disease Outcomes Consortium (PKDOC). Am J Kidney Dis 2015; 66: 583–590.
22.
Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, et al: Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep 2017; 2: 442–450.
23.
Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, et al: Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int 2018; 93: 753–760.
24.
Bhutani H, Smith V, Rahbari-Oskoui F, Mittal A, Grantham JJ, Torres VE, et al: A comparison of ultrasound and magnetic resonance imaging shows that kidney length predicts chronic kidney disease in autosomal dominant polycystic kidney disease. Kidney Int 2015; 88: 146–151.
25.
Bae KT, Tao C, Zhu F, Bost JE, Chapman AB, Grantham JJ, et al: MRI-based kidney volume measurements in ADPKD: reliability and effect of gadolinium enhancement. Clin J Am Soc Nephrol 2009; 4: 719–725.
26.
Chapman AB, Guay-Woodford LM, Grantham JJ, Torres VE, Bae KT, Baumgarten DA, et al: Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003; 64: 1035–1045.
27.
High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007; 56: 21–26.
28.
Thakral C, Abraham JL: Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. J Cutan Pathol 2009; 36: 1244–1254.
29.
Lee YR, Lee KB: Reliability of magnetic resonance imaging for measuring the volumetric indices in autosomal-dominant polycystic kidney disease: correlation with hypertension and renal function. Nephron Clin Pract 2006; 103:c173–c180.
30.
Mignani R, Corsi C, De Marco M, Caiani EG, Santucci G, Cavagna E, et al: Assessment of kidney volume in polycystic kidney disease using magnetic resonance imaging without contrast medium. Am J Nephrol 2011; 33: 176–184.
31.
Mai J, Lee VW, Lopez-Vargas P, Vladica P, Rangan GK: KHA-CARI autosomal dominant polycystic kidney disease guideline: monitoring disease progression. Semin Nephrol 2015; 35: 565–571.
32.
Turco D, Valinoti M, Martin EM, Tagliaferri C, Scolari F, Corsi C: Fully automated segmentation of polycystic kidneys from noncontrast computed tomography. A feasibility study and preliminary results. Acad Radiol 2018; 31–32.
33.
Kistler AD, Poster D, Krauer F, Weishaupt D, Raina S, Senn O, et al: Increases in kidney volume in autosomal dominant polycystic kidney disease can be detected within 6 months. Kidney Int 2009; 75: 235–241.
34.
King BF, Reed JE, Bergstralh EJ, Sheedy PF 2nd, Torres VE: Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1505–1511.
35.
Sharma K, Caroli A, Quach LV, Petzold K, Bozzetto M, Serra AL, et al: Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS One 2017; 12:e0178488.
36.
Spithoven EM, van Gastel MD, Messchendorp AL, Casteleijn NF, Drenth JP, Gaillard CA, et al: Estimation of total kidney volume in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2015; 66: 792–801.
37.
Bae KT, Commean PK, Lee J: Volumetric measurement of renal cysts and parenchyma using MRI: phantoms and patients with polycystic kidney disease. J Comput Assist Tomogr 2000; 24: 614–619.
38.
Higashihara E, Nutahara K, Okegawa T, Tanbo M, Hara H, Miyazaki I, et al: Kidney volume estimations with ellipsoid equations by magnetic resonance imaging in autosomal dominant polycystic kidney disease. Nephron 2015; 129: 253–262.
39.
O’Neill WC, Robbin ML, Bae KT, Grantham JJ, Chapman AB, Guay-Woodford LM, et al: Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 2005; 46: 1058–1064.
40.
Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al: Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992; 41: 1311–1319.
41.
Hammoud S, Tissier AM, Elie C, Pousset M, Knebelman B, Joly D, et al: Ultrasonographic renal volume measurements in early autosomal dominant polycystic disease: comparison with CT-scan renal volume calculations. Diagn Interv Imaging 2015; 96: 65–71.
42.
Bakker J, Olree M, Kaatee R, de Lange EE, Moons KG, Beutler JJ, et al: Renal volume measurements: accuracy and repeatability of US compared with that of MR imaging. Radiology 1999; 211: 623–628.
43.
Bae KT, Tao C, Wang J, Kaya D, Wu Z, Bae JT, et al: Novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease. Am J Nephrol 2013; 38: 333–341.
44.
Turco D, Severi S, Mignani R, Aiello V, Magistroni R, Corsi C: Reliability of total renal volume computation in polycystic kidney disease from magnetic resonance imaging. Acad Radiol 2015; 22: 1376–1384.
45.
Bae K, Park B, Sun H, Wang J, Tao C, Chapman AB, et al: Segmentation of individual renal cysts from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2013; 8: 1089–1097.
46.
Racimora D, Vivier PH, Chandarana H, Rusinek H: Segmentation of polycystic kidneys from MR images. In: Karssemeijer N, Summers RM (eds): Med Imaging. 2010, vol 7624, pp 540–550.
47.
Cohen BA, Barash I, Kim DC, Sanger MD, Babb JS, Chandarana H: Intraobserver and interobserver variability of renal volume measurements in polycystic kidney disease using a semiautomated MR segmentation algorithm. Am J Roentgenol 2012; 199: 387–393.
48.
Kline TL, Edwards ME, Korfiatis P, Akkus Z, Torres VE, Erickson BJ: Semiautomated segmentation of polycystic kidneys in T2-weighted MR images. Am J Roentgenol 2016; 207: 605–613.
49.
Corsi C, Mignani R, Turco D, Magistroni R, Severi S: Comment on the paper: “novel approach to estimate kidney and cyst volumes using mid-slice magnetic resonance images in polycystic kidney disease.” Am J Nephrol 2014; 39: 163–164.
50.
Kim Y, Ge Y, Tao C, Zhu J, Chapman AB, Torres VE, et al: Automated segmentation of kidneys from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2016; 11: 576–584.
51.
Kline TL, Korfiatis P, Edwards ME, Warner JD, Irazabal MV, King BF, et al: Automatic total kidney volume measurement on follow-up magnetic resonance images to facilitate monitoring of autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant 2016; 31: 241–248.
52.
Bae KT, Grantham JJ: Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010; 6: 96–106.
53.
Mayo Foundation and Medical Education and Research: Imaging classification of ADPKD: A simple model for selecting patients for clinical trials. Mayo ADPKD class calculator. Available from: http://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754 (accessed November 29, 2017).
54.
McEwan P, Bennett Wilton H, Ong ACM, Ørskov B, Sandford R, Scolari F, et al: A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrol 2018; 37.
55.
Ars E, Bernis C, Fraga G, Martinez V, Martins J, Ortiz A, et al: Spanish guidelines for the management of autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2014; 29(suppl 4): 95–105.
56.
Sise C, Kusaka M, Wetzel LH, Winklhofer F, Cowley BD, Cook LT, et al: Volumetric determination of progression in autosomal dominant polycystic kidney disease by computed tomography. Kidney Int 2000; 58: 2492–2501.
57.
Turco D, Busutti M, Mignani R, Magistroni R, Corsi C: Comparison of total kidney volume quantification methods in autosomal dominant polycystic disease for a comprehensive disease assessment. Am J Nephrol 2017; 373–379.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.